STOCK TITAN

iCAD to Report Third Quarter 2020 Financial Results on Thursday, November 5

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) --  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, November 5.

Thursday, November 5th @ 4:30pm ET
Domestic:                 800-908-8386
International:            212-231-2909
Conference ID:         21971485
Webcast:                  http://public.viavid.com/index.php?id=142233

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Contact:
Media Inquiries:
Amy Cook
+1-925-200-2125
acook@icadmed.com

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com

Icad Inc

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

37.69M
24.81M
5.82%
28.53%
1.71%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
NASHUA

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.